Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Amgen inc. crawled date : 2022 - 09 - 12 save search
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Published: 2022-09-12 (Crawled : 22:00) - biospace.com/
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
america global conference
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-12 (Crawled : 21:00) - globenewswire.com
ENTX | $2.27 -9.92% -11.01% 550K
|
Health Technology
|
| O: 0.71%
H: 0.72%
C: -1.42%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -4.29%
global conference
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
ENTX | $2.27 -9.92% -11.01% 550K
|
Health Technology
|
| O: 0.72%
H: 6.43%
C: 0.0%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
eb613 correlation meeting response study osteoporosis
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
MS 3 d | $89.14 2.47% 0.0% 18M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE S | $134.08 -3.12% -3.22% 310K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras response cancer
Celiac Diseases Drugs Market Report by Technavio expects growth to accelerate at 16.95% CAGR
Published: 2022-09-12 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.56%
H: 9.43%
C: 7.62%
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
GSK | $39.95 -1.36% 0.0% 2.4M
|
Health Technology
|
| O: 1.44%
H: 1.67%
C: 0.31%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
BLRX | $0.631 -1.42% -1.44% 250K
|
Health Technology
|
| O: -3.3%
H: 1.7%
C: -6.82%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
report growth market
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS 3 d | $89.14 2.47% 0.0% 18M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE S | $134.08 -3.12% -3.22% 310K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.